# A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

> **NCT06335355** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Shengdi Pharmaceutical Co., Ltd** · enrollment: 401 (estimated)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin
- **DRUG:** Camrelizumab + Pemetrexed + Carboplatin
- **DRUG:** Adebrelimab + Pemetrexed + Carboplatin

## Key facts

- **NCT ID:** NCT06335355
- **Lead sponsor:** Shanghai Shengdi Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03
- **Primary completion:** 2028-10
- **Final completion:** 2030-10
- **Target enrollment:** 401 (ESTIMATED)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06335355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06335355, "A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06335355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*